HKD 3.58
(-0.56%)
Year | EBITDA | EBITDA Growth |
---|---|---|
2023 | -72.36 Million USD | 21.87% |
2022 | -89.01 Million USD | 56.72% |
2021 | -55.86 Million USD | -467.48% |
2020 | -19.26 Million USD | -138.16% |
2019 | -14.39 Million USD | 0.0% |
Year | EBITDA | EBITDA Growth |
---|---|---|
2023 FY | - USD | 21.87% |
2023 Q1 | - HKD | 0.0% |
2023 Q2 | - HKD | 0.0% |
2023 Q3 | - HKD | 0.0% |
2022 FY | - USD | 56.72% |
2022 Q4 | - HKD | 0.0% |
2022 Q3 | - HKD | 0.0% |
2021 Q3 | -16.3 Million USD | 0.0% |
2021 Q4 | -165.18 Million USD | -913.21% |
2021 FY | - USD | -467.48% |
2020 Q4 | -5.53 Million USD | 0.0% |
2020 FY | - USD | -138.16% |
2019 FY | - USD | 0.0% |
Name | EBITDA | EBITDA Difference |
---|---|---|
Uni-Bio Science Group Limited | 91.23 Million HKD | 179.315% |
CK Life Sciences Int'l., (Holdings) Inc. | 486.79 Million HKD | 114.865% |